PDCD1 and melanoma: Furthermore, loss-of-function mutations in the upstream IFNγ-signaling regulators JAK1 and JAK2, concurrent with deletion of the wild type alleles, have been identified in two melanoma patients who failed anti-PD-1 therapy (7).